# Junta clínica — PT-pseudo_48fb60dfd22f (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_48fb60dfd22f",
  "pid": "PT-pseudo_48fb60dfd22f",
  "task": 1,
  "psa": 24.0,
  "age": 68,
  "months": 1,
  "pirads": "5",
  "psad": 0.986,
  "psav": 3.9,
  "psap": 16.9,
  "vol": 24.35,
  "dre": "Normal",
  "bx": "None",
  "cspca": 0.8596296,
  "medhx": "Hypertension, Osteoarthritis",
  "meds": "metoprolol, paracetamol PRN",
  "notes": "PSA 24 ng/mL. PI-RADS 5. PSAD 0.99. Prostate volume 24 mL. csPCa 0.86.",
  "pmhx": [
    "Hypertension",
    "Osteoarthritis"
  ],
  "allergies": [],
  "vitals": {
    "weight": "93 kg",
    "height": "189 cm",
    "bmi": "26.0",
    "bp": "130/73 mmHg",
    "hr": "68 bpm",
    "smoking": "Non-smoker",
    "last_dental": "1 yr ago",
    "flu_vax": "Oct 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "14 Feb 2025",
  "enc_ref": "Dr. T. Hendriks (GP)",
  "enc_type": "Follow-up - PSA + MRI",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Clinical reassessment sought after mpMRI acquisition and a PSA increase reaching 24.0 ng/mL."
    },
    {
      "s": "History",
      "t": "A 68-year-old mechanical engineer initiated evaluation in September 2022 due to an elevated PSA reading. He is a non-smoker, and his prior biopsy bucket remains None. Long-standing hypertension is managed with metoprolol, while osteoarthritis discomfort is addressed with paracetamol taken only when necessary. He shares a home with his wife, and adult offspring stop by every week, with their son handling administrative correspondence. Moderate lower urinary tract symptoms produce an IPSS total of 12. A stable cardiology assessment occurred during autumn 2024, accompanied by routine thyroid and vascular checks. Joint stiffness limits his mobility, necessitating a walking frame for extended distances and a ground-floor consultation room. He explicitly denies unexplained weight loss, osseous pain, or nocturnal diaphoresis."
    },
    {
      "s": "Physical examination",
      "t": "DRE — texture: symmetrically smooth; mobility: unrestricted; asymmetry: absent. The glandular surface presents without palpable nodules, aligning with a normal digital examination. General inspection notes a well-nourished individual in no acute distress, registering a BMI of 26.0. Hemodynamic parameters remain stable at 130/73 mmHg with a regular pulse of 68 bpm. Cardiovascular and respiratory auscultation yield unremarkable results."
    }
  ],
  "occupation": "mechanical engineer",
  "marital": "Married",
  "living": "Lives with partner; adult children visit weekly",
  "next_of_kin": "Adult son (primary contact)",
  "recent_other": [
    "Endocrine — thyroid screening",
    "Vascular surgery — varicose veins consult",
    "Cardiology — annual review (stable, autumn 2024)"
  ],
  "alcohol": "18 units / week",
  "exercise": "Running 3x/week, 5 km",
  "ipss": "IPSS score: 12/35 (moderate LUTS)",
  "admin": "Mobility limitation (frame); ground-floor consult room preferred.",
  "mri_hospital": "Tergooi MC",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_48fb60dfd22f
Task: 1

Encounter: Urology - outpatient on 14 Feb 2025.
Referrer: Dr. T. Hendriks (GP).
Type: Follow-up - PSA + MRI.

Clinical data (read-only — values loaded from the record):
  - 68-year-old male
  - PSA: 24.0 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.986 ng/mL²
  - PSA velocity: 3.9 ng/mL/yr
  - Prior PSA: 16.9 ng/mL
  - Prostate volume: 24.35 mL
  - Months since last PSA: 1
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: None (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.8596296 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypertension, Osteoarthritis
  - Problem list / PMHx: Hypertension, Osteoarthritis
  - Current medication: metoprolol, paracetamol PRN
  - Allergies: NKA
  - Additional notes: PSA 24 ng/mL. PI-RADS 5. PSAD 0.99. Prostate volume 24 mL. csPCa 0.86.

Vitals: weight 93 kg, height 189 cm, BMI 26.0, BP 130/73 mmHg, HR 68 bpm. Smoking: Non-smoker.

Chief complaint: Clinical reassessment sought after mpMRI acquisition and a PSA increase reaching 24.0 ng/mL.

History: A 68-year-old mechanical engineer initiated evaluation in September 2022 due to an elevated PSA reading. He is a non-smoker, and his prior biopsy bucket remains None. Long-standing hypertension is managed with metoprolol, while osteoarthritis discomfort is addressed with paracetamol taken only when necessary. He shares a home with his wife, and adult offspring stop by every week, with their son handling administrative correspondence. Moderate lower urinary tract symptoms produce an IPSS total of 12. A stable cardiology assessment occurred during autumn 2024, accompanied by routine thyroid and vascular checks. Joint stiffness limits his mobility, necessitating a walking frame for extended distances and a ground-floor consultation room. He explicitly denies unexplained weight loss, osseous pain, or nocturnal diaphoresis.

Physical examination: DRE — texture: symmetrically smooth; mobility: unrestricted; asymmetry: absent. The glandular surface presents without palpable nodules, aligning with a normal digital examination. General inspection notes a well-nourished individual in no acute distress, registering a BMI of 26.0. Hemodynamic parameters remain stable at 130/73 mmHg with a regular pulse of 68 bpm. Cardiovascular and respiratory auscultation yield unremarkable results.

Patient info: mechanical engineer; Married; Lives with partner; adult children visit weekly.
Next of kin: Adult son (primary contact).

Lifestyle: alcohol 18 units / week; exercise Running 3x/week, 5 km; IPSS score: 12/35 (moderate LUTS).

Recent other appointments: Endocrine — thyroid screening; Vascular surgery — varicose veins consult; Cardiology — annual review (stable, autumn 2024).
Admin: Mobility limitation (frame); ground-floor consult room preferred.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-CLASSIFIER

*statistical classifier; suggests a starting point, decides nothing* · vuelta 1

A classifier trained only to open the discussion, not to close it. Here is its bid.

SUGGESTION: BIOPSY   p(biopsy) = 0.75
  uncertainty  +/- 0.10 (95% CI 0.54-0.95); among patients it cannot tell apart the outcome was 0.81 of 1.00 mixed
  confidence   HIGH — in this tier it was right in every one of the 28 labelled cases it covered

It read ONLY these variables: PI-RADS, prior biopsy status, PSA, age, PSA density, DRE, prostate volume, number of problems on the list. Nothing else — not the mpMRI prose, not the PSA
trajectory, not the previous notes, not this patient's management plan. Values it could not
read for this patient: none.
Out-of-fold over 91 labelled cases (5x5 StratifiedKFold, out-of-fold): accuracy 0.714 against a
majority-class baseline of 0.615, AUC 0.789, F1(yes) 0.78.

The final call is the senior urologist's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: never biopsied. My criterion answers BIOPSY.

The criterion: sample when the mpMRI shows a PI-RADS 3 or higher lesion; defer at PI-RADS 1-2. In the labelled series this criterion matched the reading urologist in 24 of 24 cases in exactly this situation.

Like the classifier, I have read ONLY the visible panel — not the mpMRI prose, the PSA
trajectory, the previous notes or the laboratory panel. Departing from me needs a specific
finding from a document somebody actually opened, named out loud. Not a restatement of the
panel numbers I already used.

## Intervención 5 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The guideline suggests that a PI-RADS score of 3 or higher is used to trigger a biopsy. The retrieved text states, "a PI-RADS threshold of $\\ge 3$ is used to trigger biopsy [135, 226, 264, 375], at the cost of missing a small number of mainly ISUP GG 2 cancers, especially in biopsy-naïve patients or in highly selected populations with high prevalence of csPCa (in which the MRI NPV decreases) [372, 472]."

WHAT THE CLASSIFIER'S BID DOES NOT SETTLE
The classifier's suggestion of biopsy is too broad because it fails to account for the specific risk stratification provided by the guideline. It does not incorporate the PSA density threshold, which is a decisive variable in the guideline's risk-adapted matrix. Furthermore, the classifier's bid does not address the trade-off between missing ISUP GG 2 cancers and the potential for overdiagnosis, which is a key consideration in the guideline's framework.

WHAT WE STILL NEED
The mpMRI prose - The mpMRI prose shows a PI-RADS score of 5, which is $\ge 3$, which aligns with the guideline's trigger. This suggests a biopsy is indicated based on the imaging finding.
PSA density - The PSA density is $0.986 \text{ ng/mL}^2$. This value falls into the 'High' risk category ($> 0.20 \text{ ng/mL/cc}$), which is a decisive factor in the guideline's risk-adapted matrix.
Prior biopsy status - The prior biopsy status is 'None'. This is a decisive factor as the guideline notes that the trade-off changes for biopsy-naïve patients.
Prostate volume - The prostate volume is $24.35 \text{ mL}$. This value is a variable that the guideline makes decisive in its risk assessment, although the specific threshold for this variable is not explicitly stated in the retrieved text.

## Intervención 6 — MODERATOR

*chairs the discussion; sets the verification plan and the open questions* · vuelta 1

This case hinges on confirming the specific risk stratification factors mentioned by the EAU guideline, particularly regarding PSA density and the implications of being biopsy-naïve.

Before anyone argues, this is what I want established, and by whom.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> To confirm the mpMRI prose regarding lesion characteristics and extension.
  psa_trend (get_psa_trend) -> What shape does the serial PSA have — rising, flat, falling or oscillating — and over what period?

OPEN QUESTIONS for this conference — these are what the decision hangs on, and I expect them answered by name, not in general terms:
  Q1. What is the mpMRI prose to confirm the lesion characteristics and extraprostatic extension?
  Q2. What is the laboratory results panel to confirm the PSA density threshold interpretation?

On the plan itself: laboratory_results dropped: requested without naming one of the three questions that justify it (free-PSA fraction, infection or prostatitis explaining the PSA, fitness for the procedure). The DRE and the headline PSA are already on the panel. psa_trend was added to the plan: the reading urologist opened it in 87% of the labelled cases, and it carries a fact this decision turns on.

## Intervención 7 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
The mpMRI prose confirms a PI-RADS 5 lesion located in the right mid-peripheral zone, with a prostate volume of 24.35 mL, PSAD of 0.986 ng/mL/mL, and a csPCa predicted probability of 0.8596296.
psa_trend
The serial PSA has shown a rising trend from 11.8 ng/mL in Sep 2022 to 9.8 ng/mL in Dec 2023, and then increased to 24.0 ng/mL in Feb 2025.

WHAT I DID NOT OPEN
I did not open the laboratory_results panel because the moderator did not explicitly ask for it in the plan, and the DRE and headline PSA were already on the panel.

WHAT THIS SUPPORTS
FOR sampling this patient now
The mpMRI prose shows a PI-RADS 5 lesion, which is $\ge 3$, aligning with the EAU guideline trigger.
The PSA density of $0.986 \text{ ng/mL}^2$ falls into the 'High' risk category, a decisive factor in the guideline's risk-adapted matrix.
Prior biopsy status is 'None', which is a decisive factor for the guideline's risk assessment.
AGAINST sampling this patient now
nothing

WHERE THIS LEANS
The imaging findings and risk factors strongly support proceeding with a biopsy as per the guideline trigger.
LEAN: biopsy

## Intervención 8 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The registrar answered Q1 by providing the mpMRI prose confirming a PI-RADS 5 lesion, and answered the implication of the PSA trend by providing the serial PSA trend. However, the registrar did not answer Q2, as the laboratory results panel remains closed.

ALIGNMENT WITH THE CLASSIFIER
The retrieved evidence aligns with the EXPERT-CLASSIFIER's suggestion of BIOPSY, as the mpMRI prose confirms a PI-RADS 5 lesion ($\ge 3$), and the PSA density is noted as a decisive factor.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What is the mpMRI prose to confirm the lesion characteristics and extraprostatic extension? Answered by the REGISTRAR with the mpMRI prose confirming a PI-RADS 5 lesion.
Q2. What is the laboratory results panel to confirm the PSA density threshold interpretation? Not answered; the laboratory_results panel remains closed.

WHAT CARRIES WEIGHT, AND WHY
The guideline variables relevant here are the PI-RADS score ($\ge 3$) because it is the primary trigger, the PSA density ($0.986 \text{ ng/mL}^2$) because it falls into a 'High' risk category, and the prior biopsy status ('None') because it alters the risk trade-off. The room has been leaning on the imaging findings, which the guideline supports.

MY SUGGESTION TO THE CHAIR
Based on the guideline trigger (PI-RADS 5) and the presence of high-risk factors (PSA density and biopsy-naïve status), the case is in a state to be decided in favor of proceeding with a biopsy.

VERDICT: ready | SUGGEST: biopsy | MISSING: laboratory_results

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 9 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: BIOPSY   (confidence: clear)

The decision to proceed with biopsy is supported by the PI-RADS 5 finding, which is the primary trigger according to the EAU guideline. This is further strengthened by the high PSA density of 0.986 ng/mL² and the patient being biopsy-naïve. The cohort and classifier both suggested biopsy, and the registrar confirmed the PI-RADS 5 lesion and the PSA trend, leading to a clear indication for sampling.

What carried weight: age=important, psa=important, vol=important, psad=decisive, pirads=decisive, comorbidity=noted
Documents this conference opened: radiology_report, psa_trend
